Abstract
Cancer is the second leading cause of death in the United States1 and developing new technologies and methods for cancer diagnosis has been a major research field in biomedicine. For the diagnosis of cancer, especially in liver, lung, breast, prostate, and soft tissue tumors,2 it is a standard clinical practice to acquire and evaluate needle biopsy (NB) specimens before deciding on the treatment plan, such as the need for chemotherapy, radiation therapy, and/or surgical procedures.2 NB procedures include fine-needle aspiration, which often uses syringes to collect fluids for cytological evaluation, and core-needle biopsy, which collects tissue cores from suspicious regions.2 – 5 This study will focus on the collection and evaluation of NB core specimens, but the technologies and methods presented here could similarly be used to assess the cytologic content from fine-needle aspirations. NB core specimens are commonly fixed right after the acquisition and go through standard histological procedures including sectioning and staining.2 Although histopathology is the gold standard for cancer diagnosis, this conventional evaluation method often takes a day or more to generate the results.6,7 The time-consuming histological evaluation has become more of a concerning factor when the NB sampling is inadequate or non-diagnostic, which means the histology results of NB specimens fail to provide any diagnostic information, such as the presence of cancer cells. In this case, additional specimens are required, which further delays the diagnostic decisions.2,8 Therefore, there is a critical need to have a rapid screening and evaluation method of NB cores right after extraction and at the point-of-procedure.

This publication has 60 references indexed in Scilit: